Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhengzhou University
With
Zhengzhou Children's Hospital, China
The First Affiliated Hospital of Zhengzhou University
Women and Children Health Care Center of Luoyang, China
Göteborg University
NEC is one of the most severe complications in preterm neonates and is associated with high morbility and mortality. Studies have reported that EPO treatment decreases the incidence and severity of experimental NEC in animal models. Evidence from previous clinical studies about the effect of EPO treatment against NEC have all been hampered by small numbers of patients. The study is to investigate whether repeated low-dose EPO protects against NEC. Preterm infants with gestational age ≤32 weeks who are admitted to neonatal intensive care units within 72 hours after birth are randomized to EPO (500IU/kg, intravenously every other day for 2 weeks) or control group (the same volume of saline). Primary outcome is the incidence of NEC at 36 weeks of corrected age. Secondary outcome is growth and neurodevelopment at 18 months of corrected age in infants with NEC.
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Preterm infants with gestation age ≤ 32weeks
Within 72 hours after birth
Written informed consent obtained from parents
You may not be if
Genetic or metabolic diseases
Congenital abnormalities
Polycythemia
Intracranial hemorrhage grade III/IV
Unstable vital signs (such as respiration and circulation failure)